Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
94.4 PLN | -4.65% | -8.17% | -1.56% |
Strengths
- The company is one of the best yield companies with high dividend expectations.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.56% | 478M | - | ||
+17.80% | 66.73B | A- | ||
+2.92% | 49.79B | A- | ||
+19.98% | 42.5B | B+ | ||
+20.88% | 26.45B | A- | ||
+12.04% | 19.66B | C+ | ||
+1.27% | 17.18B | B+ | ||
-22.98% | 15.82B | A- | ||
+2.77% | 15.56B | B+ | ||
-9.25% | 15.41B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PCR Stock
- Ratings PCC Rokita SA